Companies › MediWound
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Oncology, Cardiovascular; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| EscharEx (EX-03) Proteolytic enzyme concentrate enriched in bromelain | – | Phase 3 | Venous Leg Ulcer (VLU) | Dec 2026 |
| EscharEx (EX-02) Proteolytic enzyme preparation (contains bromelain and papain) | – | Phase 1 | Superficial Basal Cell Carcinoma | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05157763 | EscharEx (EX-02) | Phase 1 | Superficial Basal Cell Carcinoma | Oncology | May 2022 |
| NCT06568627 | EscharEx (EX-03) | Phase 3 | Venous Leg Ulcer (VLU) | Cardiovascular | Dec 2026 |
Cash of $5m on 2025-12-31; operating cash outflow about $16m a year; runway about 4 months at that burn, to Apr 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Relay Therapeutics Aura Biosciences Salubris Biotherapeutics Immuneering UroGen Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.